BRAINBox Solutions™ utilizes blood biomarker panels and tablet-based neurocognitive testing to provide objective evidence of mild traumatic brain injury (mTBI) and predict post-injury symptom outcomes. This multi-modality approach enhances diagnostic accuracy and informs clinicians about the likelihood of recovery, addressing the need for improved assessment in traumatic brain injury cases.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AABIKL+3Founders
Product
Problem
Diagnosing mild traumatic brain injury (mTBI) relies heavily on subjective assessments, leading to potential inaccuracies and inconsistencies in diagnosis. Current methods lack objective measures to accurately predict post-injury symptom outcomes, hindering effective treatment planning and patient management. The absence of rapid, objective tools delays appropriate intervention and prolongs recovery for many patients.
Solution
BRAINBox Solutions offers a multi-modality approach that combines blood biomarker panels with tablet-based neurocognitive testing to provide objective evidence for the diagnosis and prognosis of mTBI. The system utilizes a point-of-care instrument and standard laboratory systems for biomarker analysis, alongside validated neurocognitive tools administered via tablet. An AI-driven algorithm integrates these data points to generate a TBI score, offering clinicians insights into the likelihood of post-injury symptoms and aiding in personalized treatment strategies. The TBI Evaluation Station integrates clinical data and cognitive assessments to provide an easy-to-interpret TBI score.
Target Audience
The primary audience includes clinicians in emergency departments and sports medicine, as well as neurologists and other healthcare providers involved in the diagnosis and management of patients with mild traumatic brain injury.
Features
- Blood biomarker panels covering multiple aspects of injury impact
- Point-of-care instrument for rapid, quantitative biomarker measurements
- Tablet-based neurocognitive testing for functional impact assessment
- AI-driven algorithm for objective scoring and prognosis
- Integration of biomarker and neurocognitive data for comprehensive assessment